VBI Balance Sheet Analysis From 2010 to 2024

VBIV Stock

USD 0.63 0.02 3.28%

Most indicators from VBI Vaccines' financial ratios are interrelated and interconnected. However, analyzing financial ratios indicators one by one will only give a small insight into VBI Vaccines current financial condition. On the other hand, looking into the entire matrix of financial ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out VBI Vaccines Valuation and VBI Vaccines Correlation analysis.

For more information on how to buy VBI Stock please use our How to Invest in VBI Vaccines guide.

At this time, VBI Vaccines' Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to climb to about 35.9 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 56.66 in 2024.

Most indicators from VBI Vaccines' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into VBI Vaccines current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out VBI Vaccines Valuation and VBI Vaccines Correlation analysis.

For more information on how to buy VBI Stock please use our How to Invest in VBI Vaccines guide.At this time, VBI Vaccines' Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to climb to about 35.9 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 56.66 in 2024.

	2023	2024 (projected)
Non Recurring	5.7M	5.0M
Reconciled Depreciation	2.0M	1.6M

Non Recurring Reconciled Depreciation

VBI Vaccines fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Total Current Liabilities	Accounts Payable	Net Receivables	Non Current Liabilities Total	Short Term Investments	Other Assets	Short Long Term Debt Total	Inventory	Other Current Liab	Short Term Debt	Common Stock Total Equity
Total Assets		0.89	0.49	-0.69	-0.06	0.72	0.83	0.48	0.74	-0.3	0.04	0.45	0.23	0.5	0.72	-0.11	0.12	0.38	0.57	0.27	0.19	-0.05	-0.18	0.39	-0.33	0.55
Total Stockholder Equity	0.89		0.59	-0.79	0.36	0.55	0.79	0.28	0.62	-0.55	-0.36	0.32	-0.24	0.6	0.56	-0.49	-0.28	0.49	0.27	0.36	-0.16	-0.44	-0.55	0.05	-0.51	0.17
Property Plant And Equipment Net	0.49	0.59		-0.05	0.4	-0.19	0.84	-0.11	-0.14	-0.15	-0.3	0.54	-0.19	0.97	-0.18	-0.36	-0.35	0.74	0.19	-0.04	-0.52	-0.19	-0.33	-0.47	-0.04	-0.08
Net Debt	-0.69	-0.79	-0.05		-0.27	-0.8	-0.33	-0.4	-0.83	0.67	0.35	0.09	0.24	-0.05	-0.78	0.46	0.21	-0.06	-0.23	-0.41	-0.08	0.52	0.55	-0.35	0.72	-0.16
Retained Earnings	-0.06	0.36	0.4	-0.27		-0.33	0.21	-0.47	-0.29	-0.72	-0.82	-0.09	-0.89	0.32	-0.36	-0.94	-0.82	0.44	-0.23	0.08	-0.84	-0.88	-0.93	-0.66	-0.59	-0.81
Cash	0.72	0.55	-0.19	-0.8	-0.33		0.22	0.7	0.97	-0.24	0.21	-0.02	0.33	-0.14	0.97	0.12	0.33	-0.21	0.43	0.23	0.53	0.08	0.02	0.79	-0.38	0.61
Non Current Assets Total	0.83	0.79	0.84	-0.33	0.21	0.22		0.11	0.23	-0.25	-0.14	0.59	0.07	0.8	0.2	-0.24	-0.1	0.65	0.48	0.1	-0.22	-0.11	-0.3	-0.04	-0.18	0.23
Non Currrent Assets Other	0.48	0.28	-0.11	-0.4	-0.47	0.7	0.11		0.67	-0.14	0.54	-0.1	0.41	0.01	0.7	0.21	0.51	-0.25	0.43	0.04	0.37	0.39	0.28	0.72	-0.22	0.67
Cash And Short Term Investments	0.74	0.62	-0.14	-0.83	-0.29	0.97	0.23	0.67		-0.25	0.15	0.05	0.25	-0.07	0.99	0.06	0.27	-0.12	0.36	0.36	0.53	0.0	-0.01	0.69	-0.38	0.6
Common Stock Shares Outstanding	-0.3	-0.55	-0.15	0.67	-0.72	-0.24	-0.25	-0.14	-0.25		0.45	0.17	0.57	-0.1	-0.21	0.87	0.39	-0.29	-0.24	-0.27	0.49	0.74	0.84	0.01	0.96	0.36
Other Current Assets	0.04	-0.36	-0.3	0.35	-0.82	0.21	-0.14	0.54	0.15	0.45		0.1	0.83	-0.23	0.24	0.69	0.93	-0.32	0.49	-0.31	0.63	0.86	0.83	0.6	0.32	0.63
Other Stockholder Equity	0.45	0.32	0.54	0.09	-0.09	-0.02	0.59	-0.1	0.05	0.17	0.1		0.28	0.54	0.06	0.13	0.1	0.8	0.31	0.13	0.02	0.2	0.09	-0.02	0.2	0.26
Total Liab	0.23	-0.24	-0.19	0.24	-0.89	0.33	0.07	0.41	0.25	0.57	0.83	0.28		-0.19	0.32	0.83	0.85	-0.23	0.59	-0.21	0.74	0.85	0.81	0.69	0.45	0.77
Property Plant And Equipment Gross	0.5	0.6	0.97	-0.05	0.32	-0.14	0.8	0.01	-0.07	-0.1	-0.23	0.54	-0.19		-0.11	-0.3	-0.3	0.7	0.1	0.0	-0.48	-0.1	-0.26	-0.43	0.01	-0.01
Total Current Assets	0.72	0.56	-0.18	-0.78	-0.36	0.97	0.2	0.7	0.99	-0.21	0.24	0.06	0.32	-0.11		0.12	0.35	-0.15	0.4	0.33	0.6	0.07	0.07	0.73	-0.34	0.67
Total Current Liabilities	-0.11	-0.49	-0.36	0.46	-0.94	0.12	-0.24	0.21	0.06	0.87	0.69	0.13	0.83	-0.3	0.12		0.69	-0.41	0.04	-0.13	0.73	0.88	0.92	0.47	0.78	0.64
Accounts Payable	0.12	-0.28	-0.35	0.21	-0.82	0.33	-0.1	0.51	0.27	0.39	0.93	0.1	0.85	-0.3	0.35	0.69		-0.35	0.53	-0.1	0.7	0.78	0.76	0.71	0.22	0.68
Net Receivables	0.38	0.49	0.74	-0.06	0.44	-0.21	0.65	-0.25	-0.12	-0.29	-0.32	0.8	-0.23	0.7	-0.15	-0.41	-0.35		0.17	0.22	-0.48	-0.29	-0.42	-0.36	-0.18	-0.16
Non Current Liabilities Total	0.57	0.27	0.19	-0.23	-0.23	0.43	0.48	0.43	0.36	-0.24	0.49	0.31	0.59	0.1	0.4	0.04	0.53	0.17		-0.18	0.26	0.25	0.12	0.56	-0.34	0.45
Short Term Investments	0.27	0.36	-0.04	-0.41	0.08	0.23	0.1	0.04	0.36	-0.27	-0.31	0.13	-0.21	0.0	0.33	-0.13	-0.1	0.22	-0.18		0.1	-0.38	-0.28	0.08	-0.24	0.12
Other Assets	0.19	-0.16	-0.52	-0.08	-0.84	0.53	-0.22	0.37	0.53	0.49	0.63	0.02	0.74	-0.48	0.6	0.73	0.7	-0.48	0.26	0.1		0.54	0.7	0.67	0.33	0.72
Short Long Term Debt Total	-0.05	-0.44	-0.19	0.52	-0.88	0.08	-0.11	0.39	0.0	0.74	0.86	0.2	0.85	-0.1	0.07	0.88	0.78	-0.29	0.25	-0.38	0.54		0.93	0.47	0.67	0.62
Inventory	-0.18	-0.55	-0.33	0.55	-0.93	0.02	-0.3	0.28	-0.01	0.84	0.83	0.09	0.81	-0.26	0.07	0.92	0.76	-0.42	0.12	-0.28	0.7	0.93		0.38	0.75	0.61
Other Current Liab	0.39	0.05	-0.47	-0.35	-0.66	0.79	-0.04	0.72	0.69	0.01	0.6	-0.02	0.69	-0.43	0.73	0.47	0.71	-0.36	0.56	0.08	0.67	0.47	0.38		-0.15	0.73
Short Term Debt	-0.33	-0.51	-0.04	0.72	-0.59	-0.38	-0.18	-0.22	-0.38	0.96	0.32	0.2	0.45	0.01	-0.34	0.78	0.22	-0.18	-0.34	-0.24	0.33	0.67	0.75	-0.15		0.25
Common Stock Total Equity	0.55	0.17	-0.08	-0.16	-0.81	0.61	0.23	0.67	0.6	0.36	0.63	0.26	0.77	-0.01	0.67	0.64	0.68	-0.16	0.45	0.12	0.72	0.62	0.61	0.73	0.25

Click cells to compare fundamentals

VBI Vaccines Account Relationship Matchups

VBI Vaccines fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	122.2M	209.4M	210.3M	155.1M	87.0M	73.5M
Net Debt	(29.4M)	(92.9M)	(89.9M)	(10.4M)	29.4M	30.8M
Retained Earnings	(262.4M)	(308.6M)	(378.4M)	(489.6M)	(582.4M)	(553.3M)
Cash	44.2M	93.8M	121.7M	62.6M	23.7M	28.9M
Other Current Assets	450K	1.3M	2.2M	8.4M	4.0M	4.2M
Total Liab	33.9M	37.7M	66.4M	90.9M	79.4M	83.4M
Total Current Assets	47.0M	132.0M	130.3M	77.7M	36.2M	33.0M
Accounts Payable	1.1M	3.7M	4.3M	13.0M	6.4M	6.8M
Net Receivables	56K	201K	77K	8K	94K	0.0
Other Assets	620K	2.2M	1.3M	1.4M	1.6M	1.6M
Inventory	1.1M	2.2M	2.6M	6.6M	8.5M	8.9M
Other Current Liab	12.9M	12.4M	26.9M	22.6M	10.3M	6.4M
Short Term Debt	14.8M	944K	839K	972K	51.7M	54.3M
Common Stock	285.0M	403.5M	442.2M	442.3M	454.2M	247.1M
Net Tangible Assets	25.3M	107.3M	79.5M	3.7M	4.2M	4.0M
Intangible Assets	60.8M	62.2M	62.1M	58.3M	36.5M	47.5M
Other Liab	3.4M	3.4M	2.9M	2.7M	3.1M	2.7M
Short Long Term Debt	1.6M	1.1M	14.8M	50.8M	58.4M	61.3M
Capital Surpluse	66.4M	75.5M	81.6M	90.0M	103.5M	75.2M
Good Will	8.3M	2.2M	2.3M	2.1M	1.1M	1.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

BAC	Bank of America
DD	Dupont De Nemours
F	Ford Motor

When determining whether VBI Vaccines is a strong investment it is important to analyze VBI Vaccines' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact VBI Vaccines' future performance. For an informed investment choice regarding VBI Stock, refer to the following important reports:

How To Invest In VBI

Details

Is VBI Stock a good investment?

Details

What is VBI Vaccines' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out VBI Vaccines Valuation and VBI Vaccines Correlation analysis.

For more information on how to buy VBI Stock please use our How to Invest in VBI Vaccines guide.

You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Complementary Tools for VBI Stock analysis

When running VBI Vaccines' price analysis, check to measure VBI Vaccines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VBI Vaccines is operating at the current time. Most of VBI Vaccines' value examination focuses on studying past and present price action to predict the probability of VBI Vaccines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VBI Vaccines' price. Additionally, you may evaluate how the addition of VBI Vaccines to your portfolios can decrease your overall portfolio volatility.

	Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
	Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences
	AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities
	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules
	Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
	Money Managers Screen money managers from public funds and ETFs managed around the world
	Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
	ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
	Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets
	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
	Analyst Advice Analyst recommendations and target price estimates broken down by several categories

Is VBI Vaccines' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VBI Vaccines. If investors know VBI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VBI Vaccines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(9.79)

Revenue Per Share

0.689

Quarterly Revenue Growth

19.896

Return On Assets

(0.29)

Return On Equity

(2.20)

The market value of VBI Vaccines is measured differently than its book value, which is the value of VBI that is recorded on the company's balance sheet. Investors also form their own opinion of VBI Vaccines' value that differs from its market value or its book value, called intrinsic value, which is VBI Vaccines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VBI Vaccines' market value can be influenced by many factors that don't directly affect VBI Vaccines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between VBI Vaccines' value and its price as these two are different measures arrived at by different means. Investors typically determine if VBI Vaccines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VBI Vaccines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

VBI Balance Sheet Analysis From 2010 to 2024

VBI Vaccines fundamental ratios Correlations

VBI Vaccines Account Relationship Matchups

High Positive Relationship

High Negative Relationship

VBI Vaccines fundamental ratios Accounts

Also Currently Popular

Complementary Tools for VBI Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 0.99	Cash And Short Term Investments
Property Plant And Equipment Gross	+ 0.97	Property Plant And Equipment Net
Cash And Short Term Investments	+ 0.97	Cash
Total Current Assets	+ 0.97	Cash
Short Term Debt	+ 0.96	Common Stock Shares Outstanding
Accounts Payable	+ 0.93	Other Current Assets

Total Current Liabilities	- 0.94	Retained Earnings
Inventory	- 0.93	Retained Earnings
Total Liab	- 0.89	Retained Earnings
Short Long Term Debt Total	- 0.88	Retained Earnings
Other Assets	- 0.84	Retained Earnings
Cash And Short Term Investments	- 0.83	Net Debt